Currencies / HUMA
HUMA: Humacyte Inc
2.31
USD
0.16
(6.48%)
HUMA exchange rate has changed by -6.48% for today. During the day, the instrument was traded at a low of 2.25 and at a high of 2.48.
Follow Humacyte Inc dynamics. Real-time quotes will help you quickly react to market changes. By switching between different timeframes, you can monitor exchange rate trends and dynamics by minutes, hours, days, weeks, and months. Use this information to forecast market changes and to make informed trading decisions.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
HUMA News
- Benzinga Gold Falls 1%; ProKidney Shares Spike Higher - Apogee Therapeutics (NASDAQ:APGE), Blue Gold (NASDAQ:BGL)
- Investing Humacyte stock soars after Symvess gains DOD electronic catalog listing
- Investing Humacyte’s Symvess gains DOD electronic catalog listing approval
- Investing BTCC Exchange Reports Remarkable Q2 2025 Performance with $957 Billion Trading Volume
- Seeking Alpha Humacyte: Revenue Ramp From Symvess Incoming (NASDAQ:HUMA)
- Investing Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting
- Seeking Alpha Humacyte Paradoxically Scales Back As Symvess Begins Its Long Journey (NASDAQ:HUMA)
- Investing Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
- Investing Humacyte at H.C. Wainwright Conference: Promising Developments in SimVess
- Investing Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
- Investing Benchmark cuts Humacyte stock target to $14, maintains Buy rating
- Benzinga Small-Caps Explode Higher As Tariff Fears Ease: Humacyte, Forward Air, FormFactor Top Russell 2000 - FormFactor (NASDAQ:FORM), FTAI Aviation (NASDAQ:FTAI)
- Seeking Alpha Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript
- Investing Humacyte shares tumble 10% as Q4 loss narrows but revenue remains elusive
- Investing Humacyte CEO addresses concerns in NYT over FDA approval of Symvess
- Seeking Alpha Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel (NASDAQ:HUMA)
- Benzinga Why Humacyte (HUMA) Stock Is Falling Sharply - Humacyte (NASDAQ:HUMA)
- Investing Humacyte stock plunges on public offering pricing
- Benzinga Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Chewy (NYSE:CHWY), Bausch Health Companies (NYSE:BHC)
- Benzinga US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert - CISO Global (NASDAQ:CISO)
- Benzinga Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - AquaBounty Techs (NASDAQ:AQB), Benson Hill (NASDAQ:BHIL)
- Benzinga Humacyte Shares Plunge After Hours: Here's Why - Humacyte (NASDAQ:HUMA)
- Seeking Alpha Humacyte: Symvess Approval And Launch Are Just The First Steps To Adoption
Daily Range
2.25
2.48
Year Range
1.15
9.68
- Previous Close
- 2.51
- Open
- 2.47
- Bid
- 2.31
- Ask
- 2.61
- Low
- 2.25
- High
- 2.48
- Volume
- 3.483 K
- Daily Change
- -6.48%
- Month Change
- 9.48%
- 6 Months Change
- -47.50%
- Year Change
- -75.84%
12 July, Saturday